“…These macrocyclic carriers boast well-defined nanosized structures, utilizing their preorganized cavities for equivalent loading and encapsulation of drug molecules. − Moreover, they can achieve controlled drug release by incorporating a suitable stimulus-responsiveness. For example, our previously developed macrocyclic carriers based on azocalixarenes have demonstrated not only strong binding affinities but also hypoxia-triggered release for various drugs, rendering them to be a versatile platform for the treatment of many hypoxia-related diseases. − Besides, the exclusive formation of an intramolecular self-included complex, rather than an intermolecular supramolecular polymer or assembly, can be achieved by selecting an appropriately sized covalent spacer to connect a macrocyclic carrier with its guest, such as a drug molecules. − Owing to the concentration-independent nature of intramolecular encapsulation, it can effectively prevent off-target leakage of drugs during in vivo circulation. , Therefore, the unique intramolecular inclusion feature of SMNMs not only effectively encapsulates and protects drugs but also prevents off-target leakage, thereby significantly enhancing the stability of drugs in complex physiological environments and reducing drug side effects. Additionally, the characteristics of being a single component and molecularly dispersed confer advantages, such as ease of preparation and good reproducibility.…”